Abstract Number: 1826 • 2017 ACR/ARHP Annual Meeting
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Background/Purpose: Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than…Abstract Number: 1827 • 2017 ACR/ARHP Annual Meeting
Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial
Background/Purpose: Nails are frequently involved in psoriasis and represent one of the most difficult to treat manifestations of the disease. This study evaluated the comparative…Abstract Number: 1828 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
Background/Purpose: Secukinumab (SEC) improved the signs and symptoms of AS in 2 Phase 3 studies (MEASURE 1 and 2).1,2 Here, we present interim results through…Abstract Number: 1829 • 2017 ACR/ARHP Annual Meeting
Patterns and Predictors of Progression of Sacroiliitis in Psoriatic Arthritis and Its Relationship with Human Leukocyte Antigen (HLA) Alleles. Results from the Toronto Cohort
Background/Purpose: Psoriatic arthritis (PsA) is clinically heterogeneous, with broad phenotypes of musculoskeletal (MSK) involvement including peripheral arthritis, enthesitis, dactylitis, and axial involvement. Sacroiliitis (SI) in…Abstract Number: 1830 • 2017 ACR/ARHP Annual Meeting
Bone Marrow Edema in Sacroiliac Joints of Young Athletes Is Common and Shows Most Frequently in the Posterior Lower Ilium
Background/Purpose: Low grade bone marrow edema (BME) was reported in the sacroiliac joints (SIJ) of up to 25% of healthy individuals and mechanical back pain…Abstract Number: 1831 • 2017 ACR/ARHP Annual Meeting
A Positive MRI of the Sacroiliac Joints Is Not Specific for Axial Spondyloarthritis but Frequently Occurs in Healthy Individuals
Background/Purpose: Inflammation shown on MRI of the sacroiliac joint (MRI-SI) is prevalent in axSpA (±30%) but the specificity is not well known, hence we compared…Abstract Number: 1832 • 2017 ACR/ARHP Annual Meeting
Gut Dysbiosis Contributes to Autoimmune Pathogenesis in Lupus-Prone Mice
Background/Purpose: Multiple studies have demonstrated that commensal bacteria play an immunoregulatory role and that gut dysbiosis is associated with inflammatory diseases. This study was conducted…Abstract Number: 1833 • 2017 ACR/ARHP Annual Meeting
iRhom2 Deficiency Protects Fcgr2b-/- Lupus-Prone Mice from Kidney Damage By Modulating ADAM17-Dependent Shedding of TNF-α and EGFR Ligand
Background/Purpose: A disintegrin and metalloprotease 17 (ADAM17) controls ecto-domain shedding of TNFα and epithelial-growth factor ligands (EGFR) such as heparin-binding EGF (HB-EGF). TNFa and HB-EGF…Abstract Number: 1834 • 2017 ACR/ARHP Annual Meeting
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Background/Purpose: There is great interest in developing new treatment approaches for systemic lupus erythematosus (SLE), but the biologic therapies under investigation over the past several…Abstract Number: 1835 • 2017 ACR/ARHP Annual Meeting
Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Background/Purpose: Neuropsychiatric symptoms of systemic lupus erythematosus (NP-SLE), including headaches, cognitive dysfunction and psychiatric disorders, appear in up to 75% of SLE patients and may…Abstract Number: 1836 • 2017 ACR/ARHP Annual Meeting
Amelioration of Neuropsychiatric Systemic Lupus Erythematosus By Fingolimod-Mediated Sphingosine-1-Phosphate Receptor Modulation
Background/Purpose: While the pathogenesis of neuropsychiatric SLE (NPSLE) is not fully understood, critical aspects of disease development include neuroinflammation and loss of brain barrier integrity.…Abstract Number: 1837 • 2017 ACR/ARHP Annual Meeting
Development of Murine SLE in the Absence of BAFF
Background/Purpose: BAFF is a vital survival and differentiation factor for B cells. In human SLE, clinical efficacy with any of 4 different BAFF antagonists is…Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…Abstract Number: 1839 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials
Background/Purpose: Randomized controlled trials (RCTs) of new SLE treatments are hampered by the lack of effective outcome measures that are responsive to change and clinically…Abstract Number: 1840 • 2017 ACR/ARHP Annual Meeting
Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial
Background/Purpose: Remission in SLE is a desirable target, however there is no gold standard for the definition of remission. An international task force agreed on…
ACR Meeting Abstracts